• Heptares Therapeutics Ltd., of Welwyn Garden City, UK, appointed Daniel Grau president.
• Icon Bioscience Inc., of Sunnyvale, Calif., named Wendy Yee Murahashi vice president of clinical development.
• Immune Design Corp., of Seattle, added Wayne R. Gombotz as chief development officer.
• Immunocore Ltd., of Oxford, UK, named Dominic Smethurst medical director.
• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., promoted Niranjan Y. Sardesai to chief operating officer.
• Insys Therapeutics Inc., of Phoenix, added Matthew Napoletano as vice president of marketing.
• Interleukin Genetics Inc., of Waltham, Mass., appointed Lynn Doucette-Stamm vice president of development.
• InteRNA Technologies BV, of Utrecht, the Netherlands, appointed Mark Vaeck and Sanne Weijzen to its board chaired by Anker Lundemose.
• Intrexon Corp., of Blacksburg, Va., appointed Krish S. Krishnan chief operating officer. It also named Robert B. Shapiro and Jeffrey B. Kindler to its board.
• Inviragen Inc., of Fort Collins, Colo., hired Gilad Gordon as chief medical officer.
• Medivation Inc., of San Francisco, promoted Sarah Noonberg to vice president of clinical development.
• Melior Pharmaceuticals Inc., of Exton, Pa., appointed John Amatruda to its scientific advisory board.
• Merganser Biotech, of Newtown Square, Pa., appointed Colin Goddard to its board.